Cantor Fitzgerald analyst Pete Stravropoulos maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and raises the price target from $36 to $40.
Palantir, Mustang Bio, DraftKings, Micron, Tesla: Why These 5 Stocks Are On Investors’ Radars Today
On Monday, major U.S. indices saw gains, with the Dow Jones Industrial Average closing nearly 0.5% higher at 38,778.10.